Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776683 | 0.93 | — | — | |
| SCHEMBL3265294 | 0.82 | MAPK1 (0.45) | ALDH1A1L3MBTL1S1PR1S1PR3S1PR5 | |
| SCHEMBL6443709 | 0.81 | ALDH1A1 (0.40) | ALDH1A1L3MBTL1S1PR1S1PR3S1PR5 | |
| SCHEMBL25226356 | 0.80 | MAPK1 (0.44) | ALDH1A1L3MBTL1S1PR1S1PR3S1PR5 | |
| Bromide SCHEMBL27935417 | 0.80 | MAPK1 (0.44) | ALDH1A1L3MBTL1S1PR1S1PR3S1PR5 | |
| Phosphine SCHEMBL27837842 | 0.80 | MAPK1 (0.44) | ALDH1A1L3MBTL1S1PR1S1PR3S1PR5 | |
| SCHEMBL20093338 | 0.80 | S1PR1 (0.44) | ALDH1A1L3MBTL1S1PR1S1PR3S1PR5 | |
| Ammonia Solution, Strong SCHEMBL7851955 | 0.80 | MAPK1 (0.44) | ALDH1A1L3MBTL1S1PR1S1PR3S1PR5 | |
| SCHEMBL1275000 | 0.80 | S1PR1 (0.44) | ALDH1A1L3MBTL1S1PR1S1PR3S1PR5 | |
| SCHEMBL1274998 | 0.80 | S1PR1 (0.44) | ALDH1A1L3MBTL1S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4338974-B2 | — | — | 2009-10-07 | — | — | JP | claimed |
| EP-1467721-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | Amgen Inc. (US) | 2004-10-20 | — | — | EP | claimed |
| JP-2004527499-A | — | — | 2004-09-09 | — | — | JP | claimed |
| WO-2002068406-A2 | SUBSTITUTED AMINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF ANGIOGENESIS | AMGEN INC. (US) | 2002-09-06 | — | — | WO | claimed |
| US-7279498-B2 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-6998414-B2 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC (US) | 2006-02-14 | — | — | US | disclosed |
| EP-1622611-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-08 | — | — | EP | disclosed |
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | ROCHE PALO ALTO LLC | 2006-01-05 | — | — | US | disclosed |
| WO-2004096213-A1 | IMIDAZOLIN-2-YLAMINOPHENYL AMIDES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | ROCHE PALO ALTO LLC | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004075-A1 | Substituted aryl amides as IP antagonists | INSR, INSRR, GIPR | ALDH1A1 2894/4885L3MBTL1 3375/4885S1PR1 275/4885 |
| US-20040220247-A1 | Substituted arylamides as IP antagonists | INSR, PTGER1, INSRR | ALDH1A1 2221/4885L3MBTL1 3337/4885S1PR1 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.